On Tuesday, Shares of eBay Inc. (NASDAQ:EBAY), gained 1.18% to $28.33.
EBay wasted no time in paring down operations following its split from PayPal last week. The online auction company said it will shut down many of its remaining standalone mobile applications, counting eBay Valet, eBay Fashion and eBay Motors, and on-demand delivery service eBay Now, according to American City Business Journals.
eBay Now, which lets users buy from nearby sellers for expedited delivery, was probably the most talked about of the four. The app was created three years ago, and operated in various areas within New York, Chicago, Dallas and San Francisco, competing with the likes of Postmates and Instacart. Reports of Now’s death surfaced as early as June 2014, and the company had already begun closing it down formerly. But now eBay is officially shutting down the entire service.
eBay Inc. operates as a technology company that enables commerce and payments on behalf of users, merchants, retailers, and brands of various sizes in the United States and internationally. It operates in three segments: Marketplaces, Payments, and Enterprise.
Shares of AbbVie Inc. (NYSE:ABBV), inclined 2.73% to $71.23, during its last trading session.
AbbVie declared that the U.S. Food and Drug Administration (FDA) approved TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) in combination with ribavirin (RBV) for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection who do not have cirrhosis. TECHNIVIE is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. The approval of TECHNIVIE marks an important advancement in providing this historically difficult-to-treat population of HCV patients an opportunity for a cure. Virologic cure is defined as a sustained virologic response (SVR), which is when the virus is no longer detectable in the patient’s blood 12 weeks after treatment (SVR12).
TECHNIVIE is not recommended for use in patients with moderate hepatic impairment (Child-Pugh B).
“Physicians have formerly had limited options when it comes to treating people living with GT4 chronic hepatitis C,” said Tarek Hassanein, M.D., professor of medicine, University of California San Diego School of Medicine. “The approval of TECHNIVIE in combination with ribavirin is important for these patients who now have an approved all-oral, interferon-free treatment option that provides a high probability of a cure.”
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Finally, MetLife, Inc. (NYSE:MET), ended its last trade with 1.21% gain, and closed at $56.27.
MetLife declared that it has loaned $505 million to an investor group comprising associates of Loews Hotels & Resorts, NBCUniversal and Hard Rock International.
The fixed-rate loan, which was used to refinance existing debt, has a term of 10 years. The loan is secured by three AAA four-diamond resort hotels, together with a central support facility all located at Universal Orlando Resort in Orlando, Fla.
The hotel properties are the Loews Portofino Bay Hotel at Universal Orlando, Hard Rock Hotel, and Loews Royal Pacific Resort at Universal Orlando, containing a total of 2,400 rooms and more than 180,000 square feet of conference space.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
